Production / Operations
Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Launches on Walmart Canada's Digital Marketplace
Walmart Canada Expansion Signals Distribution Push Amidst Sales Consolidation

Executive Summary
- Restart Life Sciences Corp.'s subsidiary, Holy Crap Foods Inc., has secured a listing on Walmart Canada's online marketplace (Walmart.ca).
- Initial product offering includes Superseed and Oatmeal Variety Pack with inventory currently in transit to fulfillment network.
- Company plans to expand product lineup based on sales data and consumer demand metrics.
- Strategic objectives include increasing brand visibility, accessing national retail traffic, and diversifying revenue channels beyond direct-to-consumer.
- CEO Steve Loutskou states this marks the beginning of broader expansion across major retail platforms.
Material Impact
- The Walmart.ca launch is a positive distribution milestone but follows the acquisition narrative already established in February 2026.
- Recent historical data indicates a sales decline: March 2026 total brand sales were $126,348 compared to $147,139 in March 2025 (approx. 14% YoY decrease).
- The Walmart launch is intended to counteract this trend but inventory is "in transit," meaning immediate revenue impact is uncertain.
- Given the sales dip reported in April 23 news and the incremental nature of a single marketplace listing, the news does not constitute a fundamental shift in valuation expectations immediately.
- It validates the acquisition strategy but does not resolve the short-term sales contraction observed post-closing.
HEAL · Price
Company Overview
- Company: Restart Life Sciences Corp. (CSE: HEAL).
- Flagship Project: Holy Crap Foods Inc., acquired in February 2026 for $1 million cash.
- Product Portfolio: Functional foods targeting gut health (Holy Crap Cereal, Superseed) and cognitive health (BrainQ, BrainBalls).
- Operations: Turnkey manufacturing facility in Gibsons, BC; distribution across Canada, US, and Caribbean markets.
- Development Status: Post-acquisition integration phase with focus on channel realignment and marketing optimization.
More from Restart Life Sciences Corp.
Jun 18, 2026 · 06:01